Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool

Health and Quality of Life Outcomes

Ming-Chin Yang¹  Elise Chia-Hui Tan¹  Jen-Kou Lin² 

[1] Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan;Section of Colon and Rectal Surgery, Taipei Veterans General Hospital, Taipei, Taiwan

关键词: Treatment cost;    Elderly;    Colorectal cancer;    Quality of life;   

Others  :  1209242
DOI  :  10.1186/s12955-015-0261-1

 received in 2014-10-21, accepted in 2015-05-09,  发布年份 2015

【 摘 要 】

Background

Colorectal cancer (CRC) is a leading cause of cancer-related deaths in developed countries and its incidence increases with age. Intravenous administration of bolus 5-fluorouracil (5-FU) and leucovorin (LV) has been a standard treatment regime for stage III CRC. However, patients generally prefer oral therapy such as Capecitabine. Studies showed that combination of oxaliplatin and capecitabine demonstrated efficacy and safety on par with treatment involving various 5-FU/LV-based regimens in elderly patients as they are in younger ones. However, little is known regarding the cost of adjuvant therapy or the effect of therapy on HRQoL. Thus the aims of this study were to evaluate the influence of different adjuvant care for stage III CRC on the HRQoL of elderly patients and to compare the economic costs associated with capecitabine-based and 5-FU/LV-based adjuvant treatments from a societal perspective in Taiwan.

Methods

A prospective, open-label, observational, multicenter study involving 123 patients aged 70 and over from 11 different centers was conducted between July 2008 and July 2011 in Taiwan. The adjusted monthly costs per patient and HRQoL were evaluated from individual-level data. The HRQoL of patients was assessed before and after adjuvant treatment. Direct and indirect costs of adjuvant treatment were estimated from a number of sources, and QoL scores were compared between groups.

Results

After correcting for baseline characteristics of patients, no significant differences were observed in the global HRQoL scores between treatment groups during the study period. According to QLQ-CR38 results, capecitabine-based therapy appeared to alleviate problems related to defecation (4.54 vs. 8.5; P = 0.011); however, micturition problems increased (9.27 vs. 7.51; P = 0.04), compared with 5-FU/LV-based treatment. The adjusted monthly treatment cost per patient was NT$27,300 for capecitabine-based treatment and NT$53,671 for 5-FU/LV-based treatment. The total cost of 5-FU/LV-based treatment was 59 % greater than that of capecitabine-based treatment.

Conclusions

Analyzing from the societal perspective in Taiwan, capecitabine-based therapy incurred lower treatment costs than 5-FU/LV-based therapy and did not jeopardize HRQoL. Therefore, capecitabine, with or without oxaliplatin, could be considered as an alternative treatment option for elderly patients with stage III CRC.

【 授权许可】

   
2015 Lin et al.; licensee BioMed Central.

【 参考文献 】

• [1]Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2:533-43.
• [2]Cancer registry annual report, 2008. Bureau of Health Promotion, Department of Health, Taiwan; 2010.
• [3]Vital statistics annual report. Department of Health, Taiwan; 2010.
• [4]National Cancer Institute. 2012. Available at http://seer.cancer.gov/statfacts/html/colorect.html#incidence-mortality. Accessed 12 March 2012.
• [5]Cancer Trends Progress Report - 2009/2010 Update. 2011. Available at http://progressreport.cancer.gov/sites/default/files/archive/report2009.pdf. Accessed 12 March 2012.
• [6]Midgley R, Kerr DJ. Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol. 2005; 2:364-9.
• [7]Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93:850-7.
• [8]Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B et al.. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: perspectives in colorectal cancer, Dublin, 2001). Eur J Cancer. 2002; 38:1429-36.
• [9]Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C et al.. Efficacy of adjuvant fluorouracil and folinic acid in colon-cancer. Lancet. 1995; 345:939-44.
• [10]Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R. 5-fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol. 2003; 14:395-9.
• [11]Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006; 17:239-45.
• [12]Lopatriello S, Amoroso D, Donati S, Alabiso O, Forti L, Fornasiero A et al.. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. Eur J Cancer. 2008; 44:2615-22.
• [13]Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004; 90:1190-7.
• [14]Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al.. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19:4097-106.
• [15]Guyatt GH, Ferrans CE, Halyard MY, Revicki DA, Symonds TL, Varricchio CG et al.. Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc. 2007; 82:1229-39.
• [16]Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G et al.. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy cooperative oncology study 0401. J Cancer Res Clin Oncol. 2009; 135:217-26.
• [17]Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJA, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012; 51:831-9.
• [18]Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW et al.. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan. Value Health. 2011; 14:647-51.
• [19]Lang HC, Wu SL. Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ. 2012; 13:347-53.
• [20]Chie WC, Yang CH, Hsu C, Yang PC. Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res. 2004; 13:257-62.
• [21]Law CC, Tak Lam WW, Fu YT, Wong KH, Sprangers MA, Fielding R. Validation of the Chinese version of the EORTC colorectal cancer-specific quality-of-life questionnaire module (QLQ-CR38). J Pain Symptom Manage. 2008; 35:203-13.
• [22]Fayers PMAN, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. EORTC, Brussels, Belgium; 2001.
• [23]Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16:139-44.
• [24]2010 report on the manpower utilization survey. Directorate-General of Budget, Accounting and Statistics, Executive Yuan, Taipei; 2010.
• [25]Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF et al.. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011; 377:1749-59.
• [26]Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Lledo G et al.. Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer. 2010; 102:59-67.
• [27]Arkenau H-T, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A et al.. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2008; 7:60-4.
• [28]Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology. 2009; 77:244-53.
• [29]Chu E, Schulman KL, McKenna EF, Cartwright T. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin Colorectal Cancer. 2010; 9:229-37.
• [30]Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB, Brouwers J. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004; 26:579-89.
• [31]Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006; 95:27-34.